Literature DB >> 1569403

Localization of sites through which C-reactive protein binds and activates complement to residues 14-26 and 76-92 of the human C1q A chain.

H Jiang1, F A Robey, H Gewurz.   

Abstract

Studies were initiated to localize the C-reactive protein (CRP) binding site on the collagen-like region (CLR) of C1q. CRP bound preferentially to the A chain of reduced C1q, in contrast to aggregated immunoglobulin G (Agg-IgG), which reacted preferentially with the C chain. A group of C1q A chain peptides, including peptides identical to residues 81-97, 76-92, and 14-26, respectively, were synthesized from predicted binding regions. Peptide 76-92 contained two proximal lysine groups, and peptide 14-26 contained four proximal arginine groups. CRP-trimers and CRP-ligand complexes did not bind to immobilized peptide 81-97, but bound avidly to immobilized peptides 76-92 and 14-26. Agg-IgG did not bind to any of the peptides. Peptide 76-92 partially, and peptide 14-26 completely, inhibited binding of CRP to intact C1q. Peptide 14-26 also blocked C consumption initiated by CRP, but not by IgG. Replacement of the two prolines with alanines, or scrambling the order of the amino acids, resulted in loss of ability of peptide 14-26 to inhibit C1q binding and C activation by CRP, indicating a sequence specificity, and not a charge specificity alone, as the basis for the inhibitory activity of the peptide. Similar investigations with scrambled peptides showed a sequence specificity for the effects of peptide 76-92 as well. DNA and heparin inhibited binding of CRP trimers to intact C1q, as well as to each peptide 14-26 and 76-92, suggesting involvement of these regions in C1q-CLR binding reactions generally. Collectively, these data identify two cationic regions within residues 14-26 and 76-92 of the C1q A chain CLR as sites through which CRP binds and activates the classical C pathway, and suggest that these residues represent significant regions for C1q CLR binding reactions generally. To our knowledge, this represents the first delineation of sites on C1q through which binding and activation of the classical C pathway can occur.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1569403      PMCID: PMC2119198          DOI: 10.1084/jem.175.5.1373

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  29 in total

1.  The C1q subunit of the first component of complement binds to laminin: a mechanism for the deposition and retention of immune complexes in basement membrane.

Authors:  J F Bohnsack; A J Tenner; G W Laurie; H K Kleinman; G R Martin; E J Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

2.  The binding site for C1q on IgG.

Authors:  A R Duncan; G Winter
Journal:  Nature       Date:  1988-04-21       Impact factor: 49.962

3.  Interaction of C1q with DNA.

Authors:  M R Van Schravendijk; R A Dwek
Journal:  Mol Immunol       Date:  1982-09       Impact factor: 4.407

4.  Interaction of C-reactive protein complexes with the complement system. II. Consumption of guinea pig complement by CRP complexes: requirement for human C1q.

Authors:  J E Volanakis; M H Kaplan
Journal:  J Immunol       Date:  1974-07       Impact factor: 5.422

5.  Purification and radiolabeling of human C1q.

Authors:  A J Tenner; P H Lesavre; N R Cooper
Journal:  J Immunol       Date:  1981-08       Impact factor: 5.422

6.  Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q.

Authors:  H X Jiang; J N Siegel; H Gewurz
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

7.  Characterization and organization of the genes encoding the A-, B- and C-chains of human complement subcomponent C1q. The complete derived amino acid sequence of human C1q.

Authors:  G C Sellar; D J Blake; K B Reid
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

Review 8.  C-reactive protein and the acute phase response.

Authors:  H Gewurz; C Mold; J Siegel; B Fiedel
Journal:  Adv Intern Med       Date:  1982

9.  Interaction between complement subcomponent C1q and bacterial lipopolysaccharides.

Authors:  A Zohair; S Chesne; R H Wade; M G Colomb
Journal:  Biochem J       Date:  1989-02-01       Impact factor: 3.857

10.  Interactions of C-reactive protein with the complement system. I. Protamine-induced consumption of complement in acute phase sera.

Authors:  J Siegel; R Rent; H Gewurz
Journal:  J Exp Med       Date:  1974-09-01       Impact factor: 14.307

View more
  19 in total

Review 1.  Local neuroinflammation and the progression of Alzheimer's disease.

Authors:  Patrick L McGeer; Edith G McGeer
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

2.  Development of a humanized C1q A chain knock-in mouse: assessment of antibody independent beta-amyloid induced complement activation.

Authors:  Ming Li; Rahasson R Ager; Deborah A Fraser; Natalia O Tjokro; Andrea J Tenner
Journal:  Mol Immunol       Date:  2008-04-08       Impact factor: 4.407

Review 3.  C-reactive protein as a pro-inflammatory mediator in cardiovascular disease by its ability to activate complement: additional proof and hypothetical mechanisms.

Authors:  W K Lagrand; R Nijmeijer; H W M Niessen; C A Visser; W Th Hermens; C E Hack
Journal:  Neth Heart J       Date:  2002-04       Impact factor: 2.380

4.  Interaction between complement subcomponent C1q and the Klebsiella pneumoniae porin OmpK36.

Authors:  S Albertí; G Marqués; S Hernández-Allés; X Rubires; J M Tomás; F Vivanco; V J Benedí
Journal:  Infect Immun       Date:  1996-11       Impact factor: 3.441

5.  Linking inflammation and thrombosis: Role of C-reactive protein.

Authors:  William P Fay
Journal:  World J Cardiol       Date:  2010-11-26

6.  Monitoring of immunotherapy with cytokines or monoclonal antibodies.

Authors:  C Erik Hack
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

7.  Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to chromatin and nucleoli.

Authors:  M B Pepys; S E Booth; G A Tennent; P J Butler; D G Williams
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Mediation of a non-proteolytic activation of complement component C3 by phospholipid vesicles.

Authors:  Yvonne Klapper; Osama A Hamad; Yuji Teramura; Gero Leneweit; G Ulrich Nienhaus; Daniel Ricklin; John D Lambris; Kristina N Ekdahl; Bo Nilsson
Journal:  Biomaterials       Date:  2014-01-23       Impact factor: 12.479

9.  Identification of the gC1qR sites for the HIV-1 viral envelope protein gp41 and the HCV core protein: Implications in viral-specific pathogenesis and therapy.

Authors:  Lina Pednekar; Alisa Valentino; Yan Ji; Nithin Tumma; Christopher Valentino; Adarsh Kadoor; Kinga K Hosszu; Mahalakshmi Ramadass; Richard R Kew; Uday Kishore; Ellinor I B Peerschke; Berhane Ghebrehiwet
Journal:  Mol Immunol       Date:  2016-04-23       Impact factor: 4.407

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.